Elzovantinib

Description	TPX-0022, also known as CSF1R-IN-2, is an orally bioavailable multi-targeted kinase inhibitor with a novel three-dimensional macrocyclic structure that inhibits the MET, CSF1R (colony stimulating factor 1 receptor) and SRC kinases. Targeting CSF1R leads to the modulation of tumor-associated macrophages (TAMs), a type of immune cell that suppresses the T-cell mediated anti-tumor immune response. Inhibition of CSF1R with TPX-0022 is a promising therapeutic strategy as a single agent or in combination with standard of care chemotherapy and immunotherapy in various solid tumors.
Pathways	Angiogenesis/Protein Tyrosine Kinase
Targets	Src/Bcr Abl

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.